An EGFRvIII-targeted immune-based therapy could potentially treat glioblastoma
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical…
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma.